Nurix Therapeutics, Inc. $NRIX Stock Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA decreased its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 51.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,130,453 shares of the company’s stock after selling 1,220,779 shares during the quarter. Pictet Asset Management Holding SA owned approximately 1.03% of Nurix Therapeutics worth $26,798,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. AlphaCentric Advisors LLC boosted its holdings in shares of Nurix Therapeutics by 4.5% during the 3rd quarter. AlphaCentric Advisors LLC now owns 27,006 shares of the company’s stock valued at $640,000 after buying an additional 1,161 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Nurix Therapeutics in the 3rd quarter worth about $126,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Nurix Therapeutics by 15.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,936 shares of the company’s stock worth $448,000 after acquiring an additional 2,479 shares in the last quarter. Sterling Capital Management LLC increased its stake in shares of Nurix Therapeutics by 310.4% in the 3rd quarter. Sterling Capital Management LLC now owns 2,885 shares of the company’s stock worth $68,000 after acquiring an additional 2,182 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in Nurix Therapeutics by 95.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,270 shares of the company’s stock valued at $30,000 after acquiring an additional 620 shares during the period.

Insider Activity at Nurix Therapeutics

In other Nurix Therapeutics news, Director Julia P. Gregory sold 22,583 shares of Nurix Therapeutics stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $23.40, for a total value of $528,442.20. Following the completion of the transaction, the director directly owned 10,750 shares of the company’s stock, valued at approximately $251,550. The trade was a 67.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Hans van Houte sold 4,769 shares of Nurix Therapeutics stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $15.63, for a total transaction of $74,539.47. Following the completion of the transaction, the chief financial officer directly owned 42,745 shares of the company’s stock, valued at $668,104.35. This trade represents a 10.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 38,499 shares of company stock valued at $893,645. 6.70% of the stock is owned by insiders.

Nurix Therapeutics Trading Up 2.8%

NASDAQ NRIX opened at $16.33 on Thursday. Nurix Therapeutics, Inc. has a 12 month low of $12.01 and a 12 month high of $28.23. The stock’s fifty day moving average price is $23.67 and its 200-day moving average price is $20.17. The stock has a market cap of $1.78 billion, a P/E ratio of 7.07 and a beta of 1.80.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $4.73 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $5.33. The firm had revenue of $673.06 million during the quarter, compared to analyst estimates of $24.35 million. Nurix Therapeutics had a return on equity of 49.34% and a net margin of 42.01%. As a group, analysts forecast that Nurix Therapeutics, Inc. will post 1.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on NRIX. UBS Group boosted their price objective on shares of Nurix Therapeutics from $23.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. Royal Bank Of Canada cut their price objective on shares of Nurix Therapeutics from $36.00 to $35.00 and set an “outperform” rating on the stock in a report on Tuesday, October 13th. Morgan Stanley raised their target price on shares of Nurix Therapeutics from $36.00 to $38.00 and gave the company an “overweight” rating in a research note on Tuesday, July 28th. Truist Financial lowered their target price on shares of Nurix Therapeutics from $34.00 to $33.00 and set a “buy” rating for the company in a report on Tuesday, October 13th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $34.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, October 13th. Fourteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Nurix Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $34.43.

About Nurix Therapeutics

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California. Founded in 2009, it develops medicines that aim to treat cancer and other diseases by changing the levels of specific proteins inside cells. The company’s technology focuses on protein degradation, using the cell’s natural protein-disposal system to remove disease-related proteins. Nurix also researches ways to regulate protein activity through ubiquitin signaling, a process that helps control how proteins function and are broken down.